Addison's Disease Market Report 2026

Addison's Disease Market Overview

• Addison's Disease market size has reached to $2.24 billion in 2025 • Expected to grow to $3.53 billion in 2030 at a compound annual growth rate (CAGR) of 9.4% • Growth Driver: Growing Incidence Of Autoimmune Disorders Fuels The Market • Market Trend: Innovative Regenerative Approaches Pave The Way For New Treatments In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Addison's Disease Market?

Addison's disease is a rare disorder where the adrenal glands produce insufficient amounts of cortisol and aldosterone due to damage, caused by an autoimmune response. Symptoms include fatigue, muscle weakness, weight loss, low mood, and skin changes. Lifelong hormone replacement therapy is required to manage the condition and prevent severe complications such as adrenal crisis. The main types of addison's disease are primary adrenal insufficiency, secondary adrenal insufficiency, and tertiary adrenal insufficiency. Primary adrenal insufficiency is a condition where the adrenal glands produce insufficient amounts of cortisol and sometimes aldosterone due to damage or dysfunction of the adrenal glands. These conditions are managed with various drug classes, including oral corticosteroids, hydrocortisone, fludrocortisone, and corticosteroid injections. Diagnosis typically involves laboratory and imaging tests to evaluate adrenal gland function. Several end-users, such as hospitals and clinics, diagnostic laboratories, and other healthcare providers, play a role in patient care.

What Is The Addison's Disease Market Growth Forecast?

The addison's disease market size is expected to see strong growth in the next few years. It will grow to $3.53 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to development of targeted adrenal insufficiency therapies, rising adoption of patient monitoring technologies, expansion of diagnostic laboratories, increasing research in autoimmune and adrenal disorders, growth in personalized medicine initiatives. Major trends in the forecast period include rising adoption of hormone replacement therapies, increasing use of diagnostic laboratory testing, growth in hydrocortisone and fludrocortisone prescriptions, expansion of autoimmune disease research, focus on early diagnosis and patient monitoring.

Global Addison's Disease Market Segmentation

1) By Drug Type: Glucocorticoids, Mineralocorticoids, Emergency Corticosteroid Therapy 2) By Route of Administration: Oral, Injectable 3) By Diagnosis: Serum Cortisol Test, ACTH Stimulation Test, Electrolyte Testing, Imaging Tests 4) By End User: Hospitals, Specialty Endocrinology Clinics, Diagnostic Laboratories Subsegments: 1) By Glucocorticoids: Hydrocortisone, Prednisolone, Prednisone, Dexamethasone 2) By Mineralocorticoids: Fludrocortisone Acetate, Desoxycorticosterone Pivalate (DOCP) 3) By Emergency Corticosteroid Therapy: Injectable Hydrocortisone (IV/IM), Injectable Dexamethasone

What Is The Driver Of The Addison's Disease Market?

The growing prevalence of autoimmune diseases is expected to propel the growth of the addison's disease market going forward. Autoimmune diseases occur when the immune system mistakenly attacks the body's own healthy tissues, leading to inflammation and damage. Genetic predispositions, environmental factors like pollutants and dietary changes, and lifestyle influences like stress and lack of physical activity all contribute to the growing prevalence of autoimmune diseases. The growing prevalence of autoimmune diseases is increasing the likelihood of co-occurrence with Addison's disease, as many patients develop additional autoimmune conditions. For instance, in March 2025, according to the Sjögren's Foundation, a US-based non-profit organization, Autoimmune illnesses afflict more than 50 million Americans, or 8% of the country's total population. Therefore, the growing prevalence of autoimmune diseases is driving the growth of the addison's disease industry.

Key Players In The Global Addison's Disease Market

Major companies operating in the addison's disease market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Bayer AG, Sanofi SA, AbbVie Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca plc, Bristol-Myers Squibb Company, Amgen Inc., Johnson & Johnson, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Lupin Ltd.

Global Addison's Disease Market Trends and Insights

Major companies operating in the addison's disease market are focusing on innovations such as regenerative therapies to enhance treatment options, improve patient outcomes, and potentially reduce lifelong dependence on hormone replacement therapies by stimulating the body's natural adrenal function. Regenerative therapies refer to medical approaches aimed at replacing or regenerating human cells, tissues, or organs to restore normal function and promote healing in cases of injury, disease, or degeneration. For instance, in July 2024, Eton Pharmaceuticals, Inc., a US-based public pharmaceutical company that focuses on developing and commercializing innovative treatments for rare diseases, announced the FDA's acceptance of its New Drug Application (NDA) for ET-400, a proprietary formulation of hydrocortisone oral solution. ET-400 is easier to store and transport compared to other formulations that may require refrigeration. The liquid format addresses the needs of young patients who may have difficulty swallowing traditional tablets and allows for precise dosing.

What Are Latest Mergers And Acquisitions In The Addison's Disease Market?

In March 2025, CROSSJECT, a France-based specialty pharmaceutical company, partnered with Eton Pharmaceuticals, Inc., to develop and commercialize a ready-to-use hydrocortisone formulation (ET-800) to treat adrenal insufficiency crises. Through this collaboration, CROSSJECT aims to leverage Eton’s regulatory and commercial expertise in the U.S. hospital market to bring its innovative hydrocortisone therapy to patients. Eton Pharmaceuticals, Inc. is a U.S.-based rare-disease pharma company addressing adrenal insufficiency, which is the key hormonal deficiency in Addison’s disease.

Regional Outlook

North America was the largest region in the addison's disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the addison's disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the addison's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Addison's Disease Market?

The addison's disease market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The addison's disease market also includes sales of adjunct therapies, diagnostic tools, adrenocorticotropic hormone (ACTH) stimulation test kits, blood cortisol, and ACTH testing kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Addison's Disease Market Report 2026?

The addison's disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the addison's disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.